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cense.Abstract Aim of the work: The aim of the present study was to assess the lipid peroxidation (LPO)
and antioxidant status of patients with rheumatoid arthritis compared with osteoarthritis.
Patients and methods: This study included 30 RA, 30 OA patients and 15 healthy subjects.
Parameters of activity of RA patients and clinical parameters of OA patients were assessed. Eryth-
rocyte sedimentation rate (ESR), C reactive protein (CRP), serum malondialdehyde (MDA), the
activities of erythrocyte superoxide dismutase (SOD) and catalase (CAT), glutathione (GSH) level,
plasma glutathione-S-transferase (GST) activity and ceruloplasmin (Cp) level were measured.
Results: Increased MDA, plasma GST activity and Cp levels with reduction of the activities of
SOD, CAT and GSH levels were demonstrated in RA and OA patients. A positive correlation
was detected between the clinical and laboratory parameters in both RA and OA patients with
GST and Cp. A direct correlation was found between previous parameters and serum MDA in
RA. Meanwhile, a negative correlation was observed between these parameters with erythrocyte
SOD, CAT activities and GSH level. Direct correlation also existed between MDA and GST withlty of Medicine, Elgesh Street,
64626.
(A.M. El-barbary).
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180 A.M. El-barbary et al.Cp, between erythrocyte SOD with CAT activities and negative correlations of GST activity with
GSH level.
Conclusion: Increased oxidative stress in RA and OA patients have led to compensatory
changes in the levels of antioxidants. These changes provide additional protection against LPO.
These ﬁndings conﬁrm the role of oxidative stress in the pathogenesis of RA and OA, and that
LPO markers and antioxidants can serve as surrogate markers for disease activity
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Reactive oxygen species (ROS) including superoxide, hydro-
gen peroxide, and hydroxyl radicals, and their reactive prod-
ucts were classically described as harmful products of aerobic
metabolism which could be capable of causing DNA muta-
tions, lipid peroxidation (LPO) and protein oxidation [1].
Among ROS, the superoxide anion (O2 ) plays a pivotal role
in inﬂammation, particularly in patients with inﬂammatory
joint disease [2]. The enzyme superoxide dismutase (SOD) neu-
tralizes O2 by transforming it into hydrogen peroxide (H2O2)
thereby preventing the formation of highly aggressive com-
pounds such as peroxynitrite (ONOO) and hydroxyl radical
(HO) [3].
Overproduction of ROS results in oxidative stress, a delete-
rious process that can be an important mediator of damage to
cell structures, including lipids and membranes, proteins, and
DNA [4]. Prime targets of ROS attack are the polyunsaturated
fatty acids in the membrane lipids causing LPO which may
lead to disorganization of cell structure and function. Further
decomposition of peroxidized lipids yields a wide variety of
end-products, including malondialdehyde (MDA) [5]. Mea-
surement of MDA is widely used as an indicator of LPO [6].
Elevated levels of MDA have been reported in the serum
and synovial ﬂuid of RA patients [7].
Multiple defense systems against free radical-induced oxida-
tive stress, collectively called antioxidants are present in human
serum, plasma as well as erythrocytes. Most of the antioxidant
ability of serum has been attributed to the presence of ascor-
bate, transferrin and ceruloplasmin (CP). Erythrocytes are
excellently equipped to handle intracellular oxidative stress
through the combined activities of catalase (Cat), superoxide
dismutases (SODs), glutathione peroxidase (GPx), glutathione
S-transferase (GST) and glutathione (GSH) [4,8].
Osteoarthritis (OA) is one of the most common chronic dis-
eases that cause pain and physical disability in patients.
Although OA is considered as a global disease affecting all
joint tissues, cartilage degradation is the end point. The degra-
dation of cartilage results from the combination of mechanical
stress and biochemical factors, mainly metalloproteinases and
ROS. The activity of ROS is balanced by enzymatic and non-
enzymatic antioxidants, that act by inhibiting oxidative en-
zymes, scavenging free radicals or chelating ion metals [9].
Rheumatoid arthritis (RA) is a heterogeneous disease with
a spectrum of clinical severity ranging from mild arthritis to a
crippling joint disorder with internal organ involvement [10].
Although the pathophysiological basis of RA is not yet fully
understood, ROS have been implicated in its pathogenesis
[11]. It was suggested that free radical production is increased
or antioxidant defense system is destroyed in RA [12].The aim of the present study was to assess the lipid perox-
idation (LPO) and antioxidant status of patients with RA com-
pared with OA.2. Patients and methods
2.1. Study population
This study included 30 RA patients (group I) diagnosed
according to the revised criteria of the American College of
Rheumatology (ACR) [13] and 30 OA patients (group II) diag-
nosed according to the ACR criteria for classiﬁcation of OA
knee [14].
Patients were collected consecutively from those attending
the outpatient clinics of Physical Medicine, Rheumatology
and Rehabilitation department, Tanta University Hospitals,
EGYPT. All RA patients were under disease-modifying
antirheumatic drugs (DMARDs) either as monotherapy or
in combination. Almost all OA patients and the vast majority
of RA patients were consuming non-steroidal anti-inﬂamma-
tory drugs (NSAIDs) on irregular basis. Fifteen age and gen-
der matched healthy subjects were enrolled in the study as a
control group (group III).
Patients suffering from chronic disorders such as diabetes
mellitus, thyroid dysfunction, liver or kidney disease, obesity
(body mass index > 30), dyslipidemia, inﬂammatory disease,
infection, smoking, consumption of any antioxidant supple-
ments at the start of the study or in the previous month were
excluded.
All patients were subjected to:
 Careful history taking.
 Thorough clinical examination with assessment of:
In RA patients:
1. Duration of morning stiffness (MS) in minutes.
2. Disease activity score 28 (DAS28) was determined for the
evaluation of current RA activity [15]. The DAS28 consid-
ers 28-joint count for tenderness, a 28-joint count for swell-
ing, erythrocyte sedimentation rate (ESR) and the patient’s
overall assessment of well-being. DAS28 was then calcu-
lated using Webculator.
In OA patients:
1. Pain at rest and pain with movement on a visual analog
scale (VAS) of 0 to 100 mm, with 0 representing the absence
of pain.
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index for knee OA, measured as total pain score (W-
TPS), total stiffness score (W-TSS) and total physical func-
tion score (W-TPFS) [16,17].
2.2. Biochemical analysis
Fasting blood samples were collected from patients and con-
trols under aseptic precautions by venepuncture; 1.6 ml in a
citrated tube for ESR, 5.0 ml in a heparinized vial for glutathi-
one and enzyme estimations and 3.0 ml in a plain vial for ser-
um MDA and plasma CP estimations. Samples were
centrifuged as soon as possible at 2000g for 10 min at 4 C.
Serum samples were stored at 70 C until the time of analysis
of MDA. GST, Cp, and routine biochemical analysis such as
ESR, and CRP, were assessed in plasma samples. After sepa-
rating the plasma, erythrocytes were washed three times in
0.9% NaCl solution and were haemolysed by dilution in water
and stored at 20 C until used for measurement of SOD,
CAT activities and GSH concentration.
Speciﬁc laboratory investigations including:
1. Serum MDA as a marker for oxidative stress was deter-
mined using the thiobarbituric acid (TBA) method [18].
2. Erythrocyte SOD activity was assessed according to the
method of Marklund and Marklund [19], which is based
on the ability of SOD to inhibit auto-oxidation of pyrogal-
lol. One unit of SOD is described as the amount of enzyme
required to inhibit the auto-oxidation of pyrogallol by 50%
in the assay mixture and the results are expressed in units/g
Hb.
3. Erythrocyte CAT activity was assessed according to the
method of Aebi [20] which is based on the decomposition
of H202 by CAT. Enzyme activity was expressed as the ﬁrst
order kinetic constant (K) of the rate of disappearance of
H202 for 15 s as measured by decrease in absorbance at
240 nm. Results were expressed as K/gHb.
4. Erythrocyte GSH concentration was determined according
to the method of Beutler et al. [21] using 5,50-dithiobis 2-
nitrobenzoic acid as disulﬁde chromogen that is easily
reduced by sulfydryl compounds to an intensely yellow
compound. The absorbance of the reduced chromogen
was measured at 412 nm and GSH concentration was
expressed as mg per g hemoglobin.
5. Plasma GST activity was determined by incubating
CDNB (1 chloro 2, 4 dinitro benzene) with reduced
GSH in the presence of serum containing GST. 2,4-Dini-
trophenylglutathione (adduct) formed was read at 340 nm
[22].
6. Plasma ceruloplasmin was determined by p-phenylene dia-
mine oxidase activity [23].
All patients gave an informed consent for a study.
Statistics: Results were expressed as mean and standard
deviation (SD). Statistical analysis was carried out using
the SPSS program (version 10.0 software, SPSS Inc. Chi-
cago, Illinois, USA). For the comparison of RA, OA and
control groups variance analysis (one-way ANOVA) test
was used. Comparisons between each two variables were
conducted using the student t-test. Correlation betweenthe variables was examined using the Pearson’s correlation
coefﬁcient.
3. Results
A total of 30 RA patients (group I) (25 females, 5 males), their
ages ranged from 39 to 56 years (mean age 48.2 ± 7.6). The
mean disease duration was 10.33 ± 2.66 years and 30 OA knee
patients (group II) (23 females, 7 males), aged from 42 to
62 years (mean age 51.2 ± 6.4). The mean disease duration
was 9.60 ± 2.26. Demographic data of patients and healthy
subjects are shown in Table 1. There was no signiﬁcant differ-
ences in age, sex and mean body mass index values between pa-
tients and controls.
Fig. 1 depicts the clinical characteristics of OA patients. In
RA patients, the mean disease activity score (DAS-28) was
5.11 ± 0.74 with a mean value of the morning stiffness which
was 60.00 ± 35.79 min. Comparison of the biochemical
parameters of RA, OA patients and healthy controls is shown
in Table 1. It demonstrates signiﬁcantly high serum levels of
MDA and plasma GST activity in both patient groups as com-
pared with the healthy control group. There was insigniﬁcant
difference in MDA serum levels between the RA and OA
groups whereas there was statistically signiﬁcant higher plasma
GST activity in RA group as compared with OA group
(P< 0.001).
We have found signiﬁcantly lower erythrocyte SOD, CAT
activities and GSH level in group I and II compared to the
control group (P< 0.001). The difference between RA and
OA was statistically signiﬁcant. As regards plasma Cp activity,
we have found signiﬁcantly higher Cp activity in the RA group
as compared with the OA and control groups with insigniﬁcant
difference between the OA and control groups.
As regards correlation matrix (Tables 2 and 3), there was
direct correlation between MS, DAS-28, ESR and CRP with
serum MDA in RA patients, but not in OA patients. Mean-
while plasma GST and Cp activities showed direct correlation
with parameters of activity and clinical parameters in both pa-
tient groups. A signiﬁcant negative correlation was detected
between activity parameters with erythrocyte SOD, CAT activ-
ities and GSH level in RA and OA patients.
As regards intra-correlation coefﬁcients (r values) between
chemical parameters studied in patients with RA and OA,
there was positive correlation between MDA, GST with Cp,
also between erythrocyte SOD with CAT activities (P<
0.001) and signiﬁcant negative correlations of plasma GST
activities with erythrocyte GSH level (P< 0.001).4. Discussion
Excessive oxidative stress is thought to have an important role
in the pathogenesis of autoimmune diseases by enhancing the
inﬂammation, inducing apoptotic cell death, and breaking
down the immunological tolerance [24].
In the current study serum MDA was found in signiﬁcantly
high levels in RA and OA patients than in controls. Akyol et
al. [25] found a remarkable elevation in MDA levels in patients
with RA compared to controls; this was also observed in many
published reports [5,26,27]. On the other hand, Olivieri et al.
[28] reported no change in LPO in RA. Many authors sug-
Table 1 Demographic and chemical characteristics of RA, OA and controls.
Parameters Group I RA (n= 30) Group II OA (n= 30) Control group (n= 15)
Age (year) 48.22 ± 7.61 51.23 ± 6.42 46.51 ± 10.05
Sex (F/M) 25/5 23/7 10/5
BMI (kg/m2) 23.58 ± 2.45 24.24 ± 2.46 23.82 ± 2.67
Duration of disease/years 10.33 ± 2.66 9.60 ± 2.26 –
ESR (mm/h) 56.93 ± 20.81a,b 20.06 ± 5.53c 8.10 ± 3.38
CRP (mg/dl) 33.06 ± 14.13a,b 8.20 ± 3.09 3.05 ± 0.42
MDA (nmol/ml) 3.15 ± 0.77a 2.80 ± 0.19c 2.05 ± 0.453
SOD (U/g Hb) 1047.73 ± 126.40a,b 1276.06 ± 139.78c 1582 ± 219
CAT (k/gHb) 82.50 ± 7.08a,b 102.30 ± 18.40c 123.70 ± 4.27
GSH (mg/gHb) 2.09 ± 0.47a,b 3.14 ± 0.60c 3.98 ± 0.72
GST (IU/L) 8.54 ± 0.47a,b 5.00 ± 0.37c 4.30 ± 0.45
Cp (g/L) 2.56 ± 0.20a,b 0.50 ± 0.20 0.50 ± 0.03
Values represent the mean ± standard deviation.
BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MDA: serum malondialdehyde; SOD: superoxide
dismutase; CAT: catalase; GST: glutathione S-transferase; GSH: glutathione; Cp: ceruloplasmin.
a Statistically signiﬁcant, compares healthy subjects and group I (P< 0.001).
b Statistically signiﬁcant, compares group I and group II (P< 0.001).
c Statistically signiﬁcant, compares healthy subjects and group II (P< 0.001).
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Figure 1 Clinical characteristics of OA patients (VAS = visual
analog scale of 0–100 mm, W-TPS =Western Ontario and
McMaster Universities (WOMAC) index for total pain score,
W-TSS =WOMAC index for total stiffness score, W-
TPFS =WOMAC index for total physical function score).
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dation environment, which in turn could result in increased
MDA levels. As a result, LPO may have a role in the patho-
genesis of the RA. The increased MDA level in our OA
patients coincides with the results of Maneesh et al. [29] and
Rubyk et al. [30] who reported signiﬁcantly increased serum
MDA levels in OA patients compared to controls. Thus, these
ﬁndings are in keeping with possible evidence of free radical
production and damage in OA. The difference between
MDA levels in RA versus OA group was statistically insignif-
icant among our patients. This ﬁnding disagrees with many
Refs. [11,31,32] which demonstrated that MDA levels were sig-
niﬁcantly elevated in RA patients compared to OA patients
and controls. This could be attributed to less inﬂammation
in our RA patients.
Recklies et al. [33] mentioned that SOD is the ﬁrst line of de-
fense against ROS; it catalyzes the dismutation of the superox-ide anion into hydrogen peroxide. Our RA and OA patients
demonstrated signiﬁcantly low erythrocyte SOD activity than
in controls, this agrees with Karatas et al. [34] and Banford
et al. [35] who stated that antioxidant enzyme SOD activity
was found to be signiﬁcantly lower in patients of RA
compared to controls. On the other hand, some authors
[11,25] reported that SOD levels in erythrocytes of patients with
RA are not different from controls. Other authors [11,25,36]
found that SOD activity in erythrocytes in patients with RA
is signiﬁcantly decreased in comparison to patients with OA
which agrees with our ﬁnding. This decreased activity of SOD
in patients with RA was assumed to indicate a degradation pro-
cess in which SOD is degraded by free radicals during the de-
toxifying processes [25]. Meanwhile, Kalpakcioglu et al. [37]
suggested that there is a possibility that the lowered levels of
SOD activity may be due to the inhibition of the enzyme by
hydrogen peroxide, which might be an indicator of high degree
of superoxide anion production. There is controversy about
SOD activity in OA. Maneesh et al. [29] and Pinto et al. [38],
found signiﬁcant increase in SOD activity in the erythrocytes
of OA patients compared to the normal healthy controls.
Meanwhile our study showed decreased SOD activity in OA
patients compared to controls. It is possible that differences be-
tween our results and other investigators results, regarding
antioxidant status, is due to differences in the stage of the dis-
ease. Chronic joint disease may deplete antioxidant defenses
whereas acute inﬂammation can upgrade them. Ostalowska
et al. [39] have reported increased activities of SOD in synovial
ﬂuid of patients with primary and secondary knee OA. In con-
trast, Ivanova and Ivanova [40] found that there was no SOD,
no or low CAT in synovial ﬂuid (SF) from OA joints.
In the present study, the observation of signiﬁcant decrease
in the activity of CAT in RA and OA patients compared to
controls agrees with Surapaneni and Venkataramana [41]
and Sarban et al. [11] who stated that the reduced CAT level
in RA and OA is due to the its inactivation by H2O2 and sug-
gest that these enzymes may play an important role in the
rheumatic process and increased oxidative stress. Therefore,
El-Sohemy et al. [42] mentioned that increasing CAT activity
Table 3 Correlation between the clinical parameters and chemical parameters in the OA patients.
Resting pain (VAS) Moving pain (VAS) W-TPS W-TSS W-TPFS
MDA r= 0.397 r= 0.118 r= 0.406 r= 0.458 r= 0.238
P= 0.138 P= 0.667 P= 0.127 P= 0.083 P= 0.381
SOD r= 0.774* r= 0.756* r= 0.711* r= 0.516* r= 0.604*
P< 0.001 P< 0.001 P= 0.002 P< 0.020 P< 0.001
CAT r= 0.959* r= 0.886* r= 0.609* r= 0.633* r= 0.604*
P< 0.001 P< 0.001 P< 0.001 P= 0.011 P< 0.001
GSH r= 0.774* r= 0.746* r= 0.554* r= 0.802* r= 0.670*
P< 0.001 P< 0.001 P< 0.001 P< 0.001 P< 0.001
GST r= 0.776* r= 0.745* r= 0.886* r= 0.439* r= 0.457*
P< 0.001 P< 0.001 P< 0.001 P< 0.005 P< 0.043
Cp r= 0.624* r= 0.450* r= 0.964* r= 0.457* r= 0.450*
P< 0.001 P< 0.001 P< 0.001 P< 0.043 P< 0.046
VAS= visual analog scale of 0–100 mm; W-TPS =Western Ontario and McMaster Universities (WOMAC) index for total pain score; W-
TSS =WOMAC index for total stiffness score; W-TPFS =WOMAC index for total physical function score.
* Values were calculated using Pearson’s correlation coefﬁcient. Abbreviations as in Table 2.
Table 2 Correlation between the activity parameters and chemical parameters in the RA patients.
DAS-28 MS/min ESR CRP
MDA r= 0.585* r= 0.653* r= 0.665* r= 0.594*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
SOD r= 0.772 * r= 0.802* r= 0.786 * r= 0.746*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
CAT r= 0.633* r= 0.609* r= 0.615* r= 0.670*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
GSH r= 0.450* r= 0.460* r= 0.457* r= 0.534*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
GST r= 0.516* r= 0.509* r= 0.513* r= 0.460*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
Cp r= 0.556* r= 0.599* r= 0.450* r= 0.460*
P< 0.001 P< 0.001 P< 0.001 P< 0.001
DAS-28: disease activity for 28 joint indices score; MS: morning stiffness; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; MDA:
serum malondialdehyde; SOD: superoxide dismutase; CAT: catalase; GST: glutathione S-transferase; GSH: glutathione; Cp: ceruloplasmin.
* Values were calculated using Pearson’s correlation coefﬁcient.
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of ROS.
Glutathione (GSH) is an important member of the antioxi-
dant team as it has been shown to plays a key role in cellular
resistance against oxidative damage; it destroys ROS and other
free radicals by enzymatic as well as non-enzymatic
mechanisms [5]. Glutathione S- transferase (GST) is an integral
part of the biphasic oxidation/conjugation system that cata-
lyzes the conjugation of GSH with several compounds pro-
duced in vivo during oxidative stress [43,44]. In our patients,
GSH level in erythrocytes was found to be signiﬁcantly reduced
in RA and OA patients versus control group. The reduction of
GSH level was signiﬁcantly higher in RA compared to OA pa-
tients. On the other hand, plasma GST activity was higher in
both patient groups versus controls, with RA patients having
signiﬁcantly higher activity than OA patients. These ﬁndings
coincide with Hassan et al. [45] who demonstrated 50% reduc-tion in GSH level and threefold increase of GST activity in RA
patients. Raised GST activity in OA patients versus controls
was observed by Ostalowska et al. [39] and Surapaneni et al.
[41] who assumed that it could be due to its induction to coun-
ter the effect of increased oxidative stress. Pinto et al. [38]
opposed all previous reports when they stated that neither
erythrocytes GSH nor plasma GST were signiﬁcantly altered
in OA patients. Meanwhile Ostalowska et al. [39] have shown
increased activity of GST in SF of OA patients.
Ceruloplasmin (Cp) is an acute phase protein that is pri-
marily synthesized in the liver and secreted into the blood. It
is a prominent antioxidant that can scavenge ROS [5,46,47].
We observed a signiﬁcant increase in plasma Cp in RA than
OA patients and controls, while Cp in OA patients was insig-
niﬁcantly higher than in control. In agreement with our ﬁnd-
ings, many authors [48,49–54] observed increased plasma Cp
level in RA. On the other hand, Ashour et al. [55] stated that
184 A.M. El-barbary et al.the raised levels of Cp are signiﬁcantly increased in RA group,
but not in OA group. This outstanding agreement about high
Cp level in RA was emphasized by Nagler et al. [10] as Cp is
considered the principle plasma and synovial antioxidant in
RA, being responsible for up to 70% of the protective capacity
against superoxide free radicals. Nevertheless, Louro et al. [56]
stated that although the increase in the concentration of Cp
might offer an additional safeguard against oxidative stress.
It does not appear to have a beneﬁcial effect upon the activity
of the illness as evaluated by means of the biological inﬂamma-
tion markers C-reactive protein and ESR.
We demonstrated signiﬁcant positive correlation between
clinical and laboratory parameters of activity in RA (DAS-
28, MS, ESR, CRP) and OA (resting and movement pain,
W-TPS, W-TSS and W-TPFS) with GST and Cp and negative
correlation with SOD, CAT and GSH.
MDA showed direct correlation with MS, DAS-28, ESR
and CRP in RA patients with no particular correlation de-
tected for MDA in OA. Our ﬁndings agree with Sarban et
al. [11] and Baskol et al. [57] who demonstrated a signiﬁcant
correlation between ESR and MDA levels in patients with
RA, and claimed it would be useful in predicting disease activ-
ity. This correlation between MDA and antioxidants versus
parameters of activity in RA makes it possible to use them
as a surrogate measure of disease activity. We demonstrated
a signiﬁcant positive correlation between serum MDA and
erythrocyte GST activity and plasma Cp concentration, an-
other direct correlation was detected between SOD and
CAT. This correlation clariﬁes that oxidative stress leads to in-
creased antioxidant enzyme activities to restore the oxidant/
antioxidant system balance which is shifted in favor of LPO
which could lead to the tissue damage observed in OA and
RA, as conﬁrmed by Jaswal et al. [26].
In conclusion, the light of our previous ﬁndings, it is possi-
ble to conclude that increased oxidative stress in RA and OA
patients evidenced by increased serum MDA, have led to com-
pensatory changes in the levels of some antioxidants, such as
SOD, CAT, GSH, GST and Cp. These changes, in turn,
may provide additional protection against LPO. These ﬁndings
conﬁrm the role of oxidative stress in the pathogenesis of RA
and OA, and that LPO markers such MDA and antioxidants
can serve as surrogate markers for disease activity in RA
and OA.
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